These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 30465864)

  • 21. The spatiotemporal changes in dopamine, neuromelanin and iron characterizing Parkinson's disease.
    Biondetti E; Santin MD; Valabrègue R; Mangone G; Gaurav R; Pyatigorskaya N; Hutchison M; Yahia-Cherif L; Villain N; Habert MO; Arnulf I; Leu-Semenescu S; Dodet P; Vila M; Corvol JC; Vidailhet M; Lehéricy S
    Brain; 2021 Nov; 144(10):3114-3125. PubMed ID: 33978742
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Parkinson's disease and dopaminergic therapy--differential effects on movement, reward and cognition.
    Rowe JB; Hughes L; Ghosh BC; Eckstein D; Williams-Gray CH; Fallon S; Barker RA; Owen AM
    Brain; 2008 Aug; 131(Pt 8):2094-105. PubMed ID: 18577547
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Moving, fast and slow: behavioural insights into bradykinesia in Parkinson's disease.
    Herz DM; Brown P
    Brain; 2023 Sep; 146(9):3576-3586. PubMed ID: 36864683
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Motivational modulation of bradykinesia in Parkinson's disease off and on dopaminergic medication.
    Kojovic M; Mir P; Trender-Gerhard I; Schneider SA; Pareés I; Edwards MJ; Bhatia KP; Jahanshahi M
    J Neurol; 2014 Jun; 261(6):1080-9. PubMed ID: 24687892
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dopaminergic modulation of motor network dynamics in Parkinson's disease.
    Michely J; Volz LJ; Barbe MT; Hoffstaedter F; Viswanathan S; Timmermann L; Eickhoff SB; Fink GR; Grefkes C
    Brain; 2015 Mar; 138(Pt 3):664-78. PubMed ID: 25567321
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of dopamine and cognitive impairment on neural reactivity to facial emotion in Parkinson's disease.
    Dan R; Růžička F; Bezdicek O; Roth J; Růžička E; Vymazal J; Goelman G; Jech R
    Eur Neuropsychopharmacol; 2019 Nov; 29(11):1258-1272. PubMed ID: 31607424
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Parkinson's disease duration determines effect of dopaminergic therapy on ventral striatum function.
    MacDonald AA; Monchi O; Seergobin KN; Ganjavi H; Tamjeedi R; MacDonald PA
    Mov Disord; 2013 Feb; 28(2):153-60. PubMed ID: 23165957
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Conditional deletion of Ndufs4 in dopaminergic neurons promotes Parkinson's disease-like non-motor symptoms without loss of dopamine neurons.
    Choi WS; Kim HW; Tronche F; Palmiter RD; Storm DR; Xia Z
    Sci Rep; 2017 Mar; 7():44989. PubMed ID: 28327638
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Compensatory premotor activity during affective face processing in subclinical carriers of a single mutant Parkin allele.
    Anders S; Sack B; Pohl A; Münte T; Pramstaller P; Klein C; Binkofski F
    Brain; 2012 Apr; 135(Pt 4):1128-40. PubMed ID: 22434215
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Reward Prediction Errors in Drug Addiction and Parkinson's Disease: from Neurophysiology to Neuroimaging.
    García-García I; Zeighami Y; Dagher A
    Curr Neurol Neurosci Rep; 2017 Jun; 17(6):46. PubMed ID: 28417291
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of striatal dopamine depletion on cognition in de novo Parkinson's disease.
    Chung SJ; Yoo HS; Oh JS; Kim JS; Ye BS; Sohn YH; Lee PH
    Parkinsonism Relat Disord; 2018 Jun; 51():43-48. PubMed ID: 29526657
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Neural correlates of early cognitive dysfunction in Parkinson's disease.
    Weil RS; Winston JS; Leyland LA; Pappa K; Mahmood RB; Morris HR; Rees G
    Ann Clin Transl Neurol; 2019 May; 6(5):902-912. PubMed ID: 31139688
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Functional MRI in Idiopathic Parkinson's Disease.
    Filippi M; Elisabetta S; Piramide N; Agosta F
    Int Rev Neurobiol; 2018; 141():439-467. PubMed ID: 30314606
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of levodopa on corticostriatal circuits supporting working memory in Parkinson's disease.
    Simioni AC; Dagher A; Fellows LK
    Cortex; 2017 Aug; 93():193-205. PubMed ID: 28675834
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dopaminergic medication normalizes aberrant cognitive control circuit signalling in Parkinson's disease.
    Cai W; Young CB; Yuan R; Lee B; Ryman S; Kim J; Yang L; Henderson VW; Poston KL; Menon V
    Brain; 2022 Nov; 145(11):4042-4055. PubMed ID: 35357463
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ventral striatal network connectivity reflects reward learning and behavior in patients with Parkinson's disease.
    Petersen K; Van Wouwe N; Stark A; Lin YC; Kang H; Trujillo-Diaz P; Kessler R; Zald D; Donahue MJ; Claassen DO
    Hum Brain Mapp; 2018 Jan; 39(1):509-521. PubMed ID: 29086460
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Multimodal magnetic resonance imaging investigation of basal forebrain damage and cognitive deficits in Parkinson's disease.
    Gargouri F; Gallea C; Mongin M; Pyatigorskaya N; Valabregue R; Ewenczyk C; Sarazin M; Yahia-Cherif L; Vidailhet M; Lehéricy S
    Mov Disord; 2019 Apr; 34(4):516-525. PubMed ID: 30536444
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dopamine-related dissociation of cortical and subcortical brain activations in cognitively unimpaired Parkinson's disease patients OFF and ON medications.
    Kim J; Zhang K; Cai W; YorkWilliams S; Ua Cruadhlaoich MAI; Llanes S; Menon V; Poston KL
    Neuropsychologia; 2018 Oct; 119():24-33. PubMed ID: 30040957
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dopamine agonist treatment increases sensitivity to gamble outcomes in the hippocampus in de novo Parkinson's disease.
    van der Vegt JPM; Hulme OJ; Madsen KH; Buhmann C; Bloem BR; Münchau A; Helmich RC; Siebner HR
    Neuroimage Clin; 2020; 28():102362. PubMed ID: 32798910
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Selective impairment of prediction error signaling in human dorsolateral but not ventral striatum in Parkinson's disease patients: evidence from a model-based fMRI study.
    Schonberg T; O'Doherty JP; Joel D; Inzelberg R; Segev Y; Daw ND
    Neuroimage; 2010 Jan; 49(1):772-81. PubMed ID: 19682583
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.